| Previous Close | Open | Close* |
|---|---|---|
| 0.23 | 0.24 | 0.245 |
| Market Cap | Dividend Yield (Annualized) |
|---|---|
| AUD 71.598M | 0.00% |
| Day Range |
|---|
| 0.235L 0.245 H |
| 52 WEEK HIGH LOW |
|---|
| 0.17L 0.63 H |
| Last Trade | 0.245 |
|---|---|
| Change% | 6.5217 |
| 52 W H/L | 0.630/0.170 |
| EBITDA | -9.629M |
| NPAT After Abnormal Items | -9.347M |
| Equity | 40.776M |
| ROE% | -22.92% |
| Total Liabilities | 7.077M |
| Total Revenue | 14.432M |
| Cash and Cash Equivalents | 26.796M |
| Share price | 0.245 |
|---|---|
| Market Cap | 71.598M |
| Price/Gross Cash Flow | -38.34 |
| Dividend Yield Excluding Special | 0.00% |
| Ending Shares | 288.222M |
| 52-Week Range | 0.630-0.170 |
| Gross DPS (AUD) | 0 |
| Gross Dividend Yield (Annualized) | 0.00% |
| Earnings Yield | 3.040 |
| Net Tangible Asset (NTA) | 0.14 |
| P/E ratio | 32.895 |
| Sector P/E | -- |
| EPS | -3.54 |
| EV/EBITDA | -- |
| Net Profit Margin (%) | -- |
| Gross Cash Flows Per Share | -0.02 |
| Net Gearing | -64.86% |
| Sales Per Share | 0.00 |
| Book Value Per Share | 0.14 |
Noxopharm Limited is an ASX-listed clinical-stage drug development company focused on the potential treatment of a wide range of cancers. The company operates under the healthcare sector and aims to create unique anti-cancer drugs. It is backed by a solid pipeline of drug candidates including Veyonda®, the first oncology pipeline product. Housed in the non-oncology subsidiary, Nyrada Inc. are four pre-clinical R and D programs.
Suite 3 Level 4, 828 Pacific Highway, GORDON, NSW, AUSTRALIA, 2072
| Ex-Date | Net Dividend | Frank Flag | Period End Date | Type | Payable |
|---|
| Event Type | Event Date | Event Year |
|---|---|---|
| Report (Interim) | 2023-02-20 | 2023 |
| Report (Annual) | 2022-09-09 | 2022 |
| Report (Annual) | 2022-08-25 | 2022 |
| Report (Prelim) | 2022-08-25 | 2022 |